SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Solid Biosciences Inc.
Date: May 21, 2025 · CIK: 0001707502 · Accession: 0000000000-25-005441

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287325

Date
May 21, 2025
Author
Division of
Form
UPLOAD
Company
Solid Biosciences Inc.

Letter

Re: Solid Biosciences Inc. Registration Statement on Form S-3 Filed May 15, 2025 File No. 333-287325 Dear Alexander Cumbo:

May 21, 2025

Alexander Cumbo President, Chief Executive Officer and Director Solid Biosciences Inc. 500 Rutherford Avenue, Third Floor Charlestown, MA 02129

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Caroline Dotolo, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 21, 2025

Alexander Cumbo
President, Chief Executive Officer and Director
Solid Biosciences Inc.
500 Rutherford Avenue, Third Floor
Charlestown, MA 02129

 Re: Solid Biosciences Inc.
 Registration Statement on Form S-3
 Filed May 15, 2025
 File No. 333-287325
Dear Alexander Cumbo:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Caroline Dotolo, Esq.
</TEXT>
</DOCUMENT>